Interim report January-March 2015: Good growth and

  · Sales amounted to SEK 162 (119) million, corresponding to an increase of 36
percent in SEK. Sales growth was 19 percent in local currency. The acquisition
of Unisense FertiliTech A/S contributed SEK 22 million to sales. Adjusted for
this, sales growth amounted to 4 percent in local currency.
  · Operating income before depreciation and amortization (EBITDA) amounted to
SEK 54 (36) million, corresponding to a margin of 33 (31) percent. Fluctuations
in exchange rates had a positive effect of SEK 12 million on operating income
before depreciation and amortization (EBITDA).
  · Net income amounted to SEK 35 (22) million, which gave earnings per share of
SEK 1.61 (1.12).

Gothenburg, April 28, 2015

VITROLIFE AB (publ)

Thomas Axelsson, CEO
Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on April
28, 2015 at 08:00 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com) is an international medical device Group.
Vitrolife Fertility product area develops, produces and markets medical devices
for assisted reproduction. Work is also carried out to enable the use and
handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in
almost 110 markets. The company is headquartered in Gothenburg, Sweden, and
there are also offices in USA, Australia, France, Italy, United Kingdom, China,
Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/
Interim report January-March 2015: Good growth and strengthened income

Attachments
